COV · ASX

CLEO Diagnostics Ltd (ASX:COV)

AU$0.46

 -0.015 (-3.158%)
ASX:Live
17/04/2025 03:57:02 PM
HALO Price Momentum HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

COV Overview

COV Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

COV Price Chart

Key Stats

Market Cap

AU$49.47M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.16 - 0.62

Trade Value (12mth)

AU$15,824.00

1 week

22.67%

1 month

2.22%

YTD

27.78%

1 year

130%

All time high

0.62

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

-$2m

Free Cash Flow Return

-48.10%

ROIC

-89.00%

Interest Coverage

N/A

Quick Ratio

19.40

Other Data

Shares on Issue (Fully Dilluted)

129m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

COV Announcements

Latest Announcements

Date Announcements

11 April 25

Quarterly activities and cashflow report

×

Quarterly activities and cashflow report

18 March 25

CLEO Delivers Commercial Development Milestone

×

CLEO Delivers Commercial Development Milestone

27 February 25

Appendix 4D and Half Yearly Accounts

×

Appendix 4D and Half Yearly Accounts

17 February 25

Clarification to ASX Price Query

×

Clarification to ASX Price Query

07 February 25

Price Query Response

×

Price Query Response

31 January 25

Quarterly activities and cashflow report

×

Quarterly activities and cashflow report

10 December 24

CLEO Further Expands Ovarian Cancer Trial with Siles Health

×

CLEO Further Expands Ovarian Cancer Trial with Siles Health

27 November 24

Results of Annual General Meeting

×

Results of Annual General Meeting

27 November 24

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

×

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

16 October 24

Quarterly activities and cashflow report

×

Quarterly activities and cashflow report

04 October 24

Letter to Shareholders

×

Letter to Shareholders

04 October 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

23 September 24

Notice Required Under ASX Listing Rule 3.13.1

×

Notice Required Under ASX Listing Rule 3.13.1

06 September 24

Cleo Commences U.S. Clinical Trials

×

Cleo Commences U.S. Clinical Trials

28 August 24

ASX Listing Rule 4.10.19

×

ASX Listing Rule 4.10.19

27 August 24

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

27 August 24

Appendix 4E and 2024 Annual Report

×

Appendix 4E and 2024 Annual Report

07 August 24

Change of Registry Address

×

Change of Registry Address

31 July 24

CLEO Selects U.S. Clinical Trial Sites

×

CLEO Selects U.S. Clinical Trial Sites

24 July 24

Quarterly activities and cashflow report

×

Quarterly activities and cashflow report

26 June 24

Cleo Commences US Regulatory Process with FDA

×

Cleo Commences US Regulatory Process with FDA

24 June 24

Application for quotation of securities - COV

×

Application for quotation of securities - COV

14 June 24

Restricted securities to be released from escrow

×

Restricted securities to be released from escrow

29 May 24

COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark

×

COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark

29 April 24

Quarterly activities and cashflow report

×

Quarterly activities and cashflow report

COV Fundamentals

Per Share Records

Historical data

Forecast data

2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) AU$ Lock Lock Lock Lock -0.00 -0.01 -0.03 Lock Lock Lock
EPS (Fully Diluted) AU$ Lock Lock Lock Lock -0.00 -0.01 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -4,400.0 -137.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS AU$ Lock Lock Lock Lock -0.00 -0.01 -0.02 Lock Lock Lock
FCFPS AU$ Lock Lock Lock Lock 0.00 -0.01 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -1,991.8 -163.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.0 -3.2 -5.1 Lock Lock Lock
DPS AU$ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS AU$ Lock Lock Lock Lock -0.00 -0.01 0.07 Lock Lock Lock
BPS (Tangible) AU$ Lock Lock Lock Lock -0.00 -0.01 0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -478.6 740.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 129 129 117 Lock Lock Lock
Basic m Lock Lock Lock Lock 129 129 117 Lock Lock Lock

Financial Records

Historical data

Forecast data

2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses AU$m Lock Lock Lock Lock 0 2 4 Lock Lock Lock
Gross Income AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A -35.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA AU$m Lock Lock Lock Lock 0 -2 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -3,809.5 -153.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT AU$m Lock Lock Lock Lock 0 -2 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -3,911.1 -150.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income AU$m Lock Lock Lock Lock 0 -2 -4 Lock Lock Lock
Income Taxes AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income AU$m Lock Lock Lock Lock 0 -2 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -3,836.9 -117.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow AU$m Lock Lock Lock Lock 0 -1 -2 Lock Lock Lock
Capital Expenditures AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow AU$m Lock Lock Lock Lock 0 1 11 Lock Lock Lock
Free Cash Flow AU$m Lock Lock Lock Lock 0 -1 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A -180.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments AU$m Lock Lock Lock Lock 0 0 9 Lock Lock Lock
Total Assets AU$m Lock Lock Lock Lock 0 1 10 Lock Lock Lock
Long Term Debt AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt AU$m Lock Lock Lock Lock 0 1 -9 Lock Lock Lock
Total Liabilities AU$m Lock Lock Lock Lock 0 2 0 Lock Lock Lock
Equity AU$m Lock Lock Lock Lock 0 -1 9 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 0 -1 9 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -2,131.6 1,095.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -18.0 -160.6 -38.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 103.9 183.3 -40.0 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock 0.0 -404.4 -86.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock 0.0 0.0 -89.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 0.0 0.0 -48.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -51.7 -15.2 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -4.6 -0.8 2.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -468.2 -144.2 -99.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 0.2 0.3 19.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 0.2 0.3 19.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.0 41.3 99.3 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 0.0 -33.9 -417.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -18.0 -160.6 -38.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock -5.8 -1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 103.9 183.3 -40.0 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock 103.9 183.3 -40.0 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 0.0 1,926.1 2,643.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 0.0 -1,926.1 -2,643.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

COV Shortsell

Frequently Asked Questions

The current share price of CLEO Diagnostics Ltd (COV:ASX) is AU$0.46.
The 52-week high share price for CLEO Diagnostics Ltd (COV:ASX) is AU$0.62.
The 52-week low share price for CLEO Diagnostics Ltd (COV:ASX)? is AU$0.16.
CLEO Diagnostics Ltd (COV:ASX) does not pay a dividend.
CLEO Diagnostics Ltd (COV:ASX) does not pay a dividend.
CLEO Diagnostics Ltd (COV:ASX) has a franking level of 0.0%.
CLEO Diagnostics Ltd (COV:ASX) is classified in the Healthcare.
The current P/E ratio for CLEO Diagnostics Ltd (COV:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.